Caribou Biosciences, Inc. (NasdaqGS: CRBU)
Health Care · Biotechnology · US
$0.53
-4.86% today · -78.7% 1Y
Caribou Biosciences, Inc. (NasdaqGS: CRBU) operates in the Biotechnology industry within the Health Care sector. The company is valued at $57.12M and employs 97 people.
Over the last twelve months the share price has lost 78.7%, trading between 0.44 and 3.54.
Tweenvest scores Caribou Biosciences, Inc. across four factors: quality 35/100, value 46/100, growth 67/100. Its strongest factor is growth.
CRBU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $57.12M
- Revenue (TTM)
- $10.04M
- P/E
- —
- EPS
- -1.08
- Dividend yield
- —
- Beta (5Y)
- 2.31
- 52-week high
- $3.54
- 52-week low
- $0.44
- Avg volume (3M)
- —
- Shares outstanding
- 107.21M
- Employees
- 97
- Next earnings
- —
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
- ISIN
- US1420381089
- Founded
- 2011
- Listed since
- Jul 23, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Zelluna ASAOB: ZLNA | $58.51M | Nkr18.50 | -5.85% |
| Adaptin Bio, Inc.OTCPK: APTN | $57.89M | $— | — |
| Biosino Bio-Technology and Science IncorporationSEHK: 8247 | $57.71M | HK$3.13 | -0.32% |
| B&K Corporation LimitedSEHK: 2396 | $57.42M | HK$3.83 | -8.70% |
| Anti-Microbial Savior BioteQ Co., Ltd.TPEX: 6864 | $56.85M | NT$48.70 | -2.60% |
| Alps Group IncNasdaqGM: ALPS | $56.58M | $0.34 | -8.11% |
| Xilio Therapeutics, Inc.NasdaqCM: XLO | $56.26M | $8.55 | -5.52% |
| Boundless Bio, Inc.NasdaqGS: BOLD | $55.27M | $2.43 | +5.19% |
Figures last refreshed Oct 18, 2026.